CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 109 enrolled
Drug / intervention
PF-06826647 tablet +3 moredrug
Likely dose
PF-06826647 oral suspension 3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03210961
NCT03210961Phase 1Completed
CompareCT.gov

A PHASE 1, WITHIN COHORT, RANDOMIZED, DOUBLE BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06826647 IN HEALTHY SUBJECTS AND SUBJECTS WITH PLAQUE PSORIASIS

Pfizer·interventional·Posted Jul 7, 2017·Updated Mar 31, 2020

In Brief

A Phase 1 clinical trial evaluating PF-06826647 tablet, PF-06826647 oral suspension, and 2 other interventions for Plaque Psoriasis. Completed, enrolled 109 participants across 1 site.

Detailed Summary

This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJul 7, 2017
Enrollment StartJul 14, 2017
Primary CompletionJan 25, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.0 years ago

Interventions

PF-06826647 tabletdrug

PF-06826647 tablet for oral administration

PF-06826647 oral suspensiondrug

PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)

Placebo oral solution/suspensionother

placebo oral solution for the single ascending dose, first cohort only

Placebo tabletother

Matching placebo tablet